Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin
A. Calin and M. Britton
Ankylosing spondylitis affects about 1% of the population. In the past,
evaluation of therapy in the management of this disease has been hampered
by the lack of availability of objective criteria for following the
condition. By using recently developed measurements of spinal mobility and
other variables we have compared sulindac, a recently introduced
nonsteroidal antiinflammatory drug, and indomethacin in a double-blind
six-month parallel study of 30 patients. Sulindac and indomethacin have
comparable efficacy and tolerance. Advantages of sulindac include a
twice-a-day dose regimen.
